Allist Pharmaceuticals
688578 · SSE STAR Market
Public Market Listing
Live quotes, historical charts, and market capitalization for Allist Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | SHP2Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFRSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
March 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (1)
October 2028 (1)
What to watch
2029 (3)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
September 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $190M | — | — | — | report ↗ |
Allist Pharmaceuticals reported revenue of $189.9M for Q3 2025.
Figures only: this period's report disclosed no narrative text
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $722M | $75M | — | — | report ↗ |